FDA vaccine chief to step down in April / Beckers

Ella Jeffries / beckershospitalreview - Vinay Prasad, MD, the FDA’s top regulator of vaccines and cell and gene therapies, will step down at the end of April, an agency spokesperson confirmed to Becker’s. Dr. Prasad joined the agency in 2025 on a one-year sabbatical from the University of Calif…

#healthcare #publichealth #governmentpolicy #biotech #drugdevelopment #fda #vaccinesafety #infectiousdisease

FDA vaccine chief to step down in April

4 days / beckershospitalreview / Ella Jeffries

Divisive F.D.A. Vaccine Regulator Resigns

4 days / nytimes / Christina Jewett

Vinay Prasad to exit FDA again, following latest round of controversy

4 days / endpoints / Max Bayer

Friday, March 6, 2026, 6:23 pm / permalink 20292 / 3 stories in 4 days

Hospitals urge regulators to halt drugmakers’ expanded 340B data policies / Healthcare Dive

Emily Olsen / healthcaredive - The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful.

#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy #hospitaloperations #healthcarefinance

Judge dismisses Pennsylvania hospitals’ lawsuit over CVS’ 340B practices

4 days / beckershospitalreview / Ella Jeffries

Hospitals urge regulators to halt drugmakers’ expanded 340B data policies

5 days / healthcaredive / Emily Olsen

Higher heat stress leads to more cardiac ICU admissions, researchers find

6 days / medicalxpress

Hospitals decry drugmakers' expanded claims reporting policies for 340B

6 days / fiercehealthcare

Friday, March 6, 2026, 12:23 pm / permalink 20277 / 4 stories in 4 days

GOVERNMENTPOLICY Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.

More Top Stories...

FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...

FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...

CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...

Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...

City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...